440 related articles for article (PubMed ID: 19498125)
1. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
2. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
3. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
4. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
Kapoian T; O'Mara NB; Singh AK; Moran J; Rizkala AR; Geronemus R; Kopelman RC; Dahl NV; Coyne DW
J Am Soc Nephrol; 2008 Feb; 19(2):372-9. PubMed ID: 18216316
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
6. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.
Mitsopoulos E; Lysitska A; Pateinakis P; Lamprou V; Intzevidou E; Minasidis I; Katsaounou C; Kougioumtzidou O; Anagnostou N; Lemonidis N; Papadopoulou D
Int Urol Nephrol; 2020 Feb; 52(2):387-392. PubMed ID: 31894555
[TBL] [Abstract][Full Text] [Related]
9. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
Kosch M; Bahner U; Bettger H; Matzkies F; Teschner M; Schaefer RM
Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726
[TBL] [Abstract][Full Text] [Related]
11. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
12. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
13. Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
Coyne DW; Sims A; Bingel B
Nephrol Nurs J; 2008; 35(6):583-7. PubMed ID: 19260610
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
15. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Diebold M; Kistler AD
BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
[TBL] [Abstract][Full Text] [Related]
17. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients.
Sirken G; Raja R; Rizkala AR
Clin Nephrol; 2006 Nov; 66(5):348-56. PubMed ID: 17140164
[TBL] [Abstract][Full Text] [Related]
18. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study.
Koutroubakis IE; Karmiris K; Makreas S; Xidakis C; Niniraki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):421-5. PubMed ID: 16538115
[TBL] [Abstract][Full Text] [Related]
20. Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients.
Javier AM
Nephrol Nurs J; 2002 Apr; 29(2):183-6. PubMed ID: 11997953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]